Is NCT07789769 recruiting in Bloomington, IN?

Yes, NCT07789769 is currently recruiting participants at its Bloomington, IN location. This overweight , obesity clinical trial is actively enrolling qualified participants.

How do I join the overweight , obesity clinical trial in Bloomington?

To join this clinical trial in Bloomington, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Bloomington clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Overweight , Obesity Clinical Trial in Bloomington, IN

About This Overweight , Obesity Study in Bloomington

The purpose of this study is to learn whether following an online weight loss program with specific dietary and exercise goals (the 30-30-30 plan) can help improve weight loss and other markers of health when compared to an online weight loss program on its own.

Sponsor: Midwest Center for Metabolic and Cardiovascular Research

Who Can Participate

Inclusion Criteria

Individual is a male or female and 18 to 69 years of age, inclusive.

Individual has a self-reported desire to lose weight.

Individual has a body mass index (BMI) ≥27.0 and ≤45.0 kg/m2.

Individual has calculated energy needs of ≥1800 kcal/d per the Mifflin-St Jeor Equation, with an adjustment for energy expended in physical activity.

Individual must be fluent in speaking, reading, and writing in English.

Individual owns a Bluetooth-compatible smartphone capable of downloading a fitness tracking app, with a camera, and has reliable Wi-Fi connectivity at home.

Individual is judged by the Investigator to be in generally good health on the basis of medical history and screening assessments.

Individual is willing and able to undergo the scheduled study procedures, including participating in an interactive, online weight loss program for 6 months, attending virtual meetings, and striving to fulfill dietary and exercise goals.

Individual understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Exclusion Criteria

Individual has a laboratory test result of clinical significance based on the judgment of the Principal Investigator or qualified designee. Individual is unwilling or unable to make dietary changes or increase physical activity.

Individual is unable to walk ¼ mile unaided without stopping.

Individual has a health condition (e.g., chronic pain, orthopedic limitations, heart problems) that would make weight loss or unsupervised exercise unsafe or infeasible. If an individual responds "yes" to any of the questions on the Physical Activity Readiness Questionnaire (PAR-Q) during visit 1, it is up to the Investigator's discretion to determine if unsupervised exercise is safe.

Individual habitually consumes \>9 g fiber per 1000 kcal per day based on their responses on the fiber intake questionnaire.

Individual habitually engages in ≥210 minutes per week of moderate-intensity or higher physical activity based on their responses on the Stanford 7-Day Physical Activity Recall (Appendix 3).

Individual regularly consumes (≥3 times per week) protein supplements, including collagen, within 30 days of visit 1.

Individual has a fasting blood glucose ≥126 mg/dL at screening or known type 1 or type 2 diabetes mellitus or use of any hypoglycemic medication (e.g., insulin, sodium glucose cotransporter-2 inhibitors, alpha glucosidase inhibitors, biguanides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, meglitinides, sulfonylureas, glucagon-like peptide-1 (GLP-1) receptor agonists, and GLP-1/glucose-dependent insulinotropic polypeptide inhibitors), except for metformin, within 30 days of visit 1.

Individual has self-reported or clinically diagnosed bipolar disorder, psychosis, or severe depression.

Individual has been hospitalized for a psychiatric disorder during the past 12 months.

Individual has lost ≥5% of their body weight in the previous 6 months.

Individual has participated in a structured weight loss program (e.g., commercial program) within 30 days prior to visit 1.

Individual has a cardiac defibrillator or pacemaker.

Individual has a clinically significant medical condition that, in the opinion of the Investigator, could interfere with the interpretation of the study results. Health conditions may include history or presence of clinically important gastrointestinal (e.g., inflammatory bowel disease, Crohn's disease, colitis, irritable bowel syndrome, celiac disease), cardiac (e.g., angina, bypass surgery, or myocardial infarction within previous 6 months), renal, hepatic, endocrine (e.g., Cushing's disease), pulmonary, biliary, pancreatic, or neurological disorders that may affect the participant's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the Investigator.

Daily use of tobacco/nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1.

Use of hemp/marijuana products within 12 months of visit 1. Occasional use (e.g., once or twice a month) within 12 months of visit 1 is allowed but requires at least a 14-day washout prior to visit 2 (week 0) and the participant must be willing to refrain from use during the study.

Individual has uncontrolled hypertension (systolic blood pressure ≥160 millimeters of mercury (mm Hg) and/or diastolic blood pressure ≥100 mm Hg) at screening.

Individual has untreated thyroid disease or unstable use (initiation or change in dose) of thyroid hormone replacement medications within 6 months of visit 1.

Use of any prescription medication with known effects on appetite or weight (e.g., oral steroids, weight loss medications, etc.) within 30 days of visit 1. A stable dose of selective serotonin reuptake inhibitors ≥6 months is allowed.

Unstable use of any supplement known to affect energy metabolism within 30 days of visit 2.

Individual has a history of cancer in the prior 5 years, except non-melanoma skin cancer or carcinoma in situ of the cervix.

Individual has extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan, vegetarian).

Individual has a history of metabolic/bariatric surgery or plans to have any type of surgery during the study.

Individual has a history of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) either diagnosed by a health professional or self-reported.

Individual has a history of any major trauma or major surgical event within 2 months of visit 1.

Individual has signs or symptoms of an active infection of clinical significance or has taken antibiotics within 5 days prior to any visit (washout is permitted for re-scheduling of the clinic visit).

Individual has an allergy, sensitivity, or intolerance to any components of the study foods.

Individual is a female who is pregnant, planning to become pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.

Individual has been exposed to any non-registered drug product within 30 days prior to visit 1.

Individual is a participant in another research study.

Individual has a current or recent history (within 12 months prior to screening) or strong potential for illicit drug or excessive alcohol intake defined as \>14 drinks per week (1 drink = 12 ounces (oz.) beer, 5 oz. wine, or 1.5 oz. hard liquor).

Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or puts the person at undue risk.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bloomington?

Yes, this clinical trial (NCT07789769) has an active research site in Bloomington, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Overweight , Obesity Treatment Options in Bloomington, IN

If you're searching for overweight , obesity treatment options in Bloomington, IN, this clinical trial (NCT07789769) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bloomington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced overweight , obesity specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all overweight , obesity clinical trials near you to find additional studies recruiting in your area.

Overweight , Obesity Clinical Trial in Bloomington, IN

Expert Care in Bloomington

IRB Approved

No-Cost Care

Apply for This Bloomington Location

Why Participate?

Simple Process